Last reviewed · How we verify
NCT04598620: VTE-COVID-19
Non-invasive Prognostication of COVID-19 Patients by Use of Biomarkers in Exhaled Breath Condensate
trial in Covid19 in 28 participants. Completed in 1 October 2021.
1 October 2021
Quick facts
| Lead sponsor | Inger Lise Gade |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 28 |
| Start date | 19 September 2020 |
| Primary completion | 1 October 2021 |
| Estimated completion | 1 October 2021 |
| Sites | 1 location across Denmark |
Conditions studied
- Covid19 — all drugs for Covid19 →
- Corona Virus Infection — all drugs for Corona Virus Infection →
Sponsor
Inger Lise Gade
Who can join
18 and older, any sex, with Covid19 or Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this study is to assess if analysis of exhaled breath condensate (EBC) can provide useful prognostic markers for admission to the intensive care unit (ICU) due to acute respiratory insufficiency among patients with Coronavirus disease 2019 (COVID-19). Additionally, to give a characterization of the lung damage caused by COVID-19 by analysis of daily blood samples. The hypothesis is that the protein content of the EBC from COVID-19 patients who require admission to the ICU differs from the EBC from COVID-19 patients with uncomplicated hospitalization, potentially providing diagnostic markers of COVID-19 related pulmonary damage.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exhaled breath protein composition in patients hospitalised during the first wave of COVID-19.
Gade IL, Bodilsen J, Mariager T, Hertz S, et al · · 2025 · PMID 40341493 · DOI 10.1088/1752-7163/add617
Verify or expand the search:
- PubMed search for NCT04598620
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Inger Lise Gade trials
Trials by the same sponsor.
- NCT04358419 — Non-invasive Diagnosis of Invasive Pulmonary Aspergillosis by Use of Biomarkers in Exhaled Breath Condensate · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04598620 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Inger Lise Gade
- Last refreshed: 15 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04598620.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing